Physician

Mark E Johns, MD

According to 2025 Medicare claims, Mark Johns, MD (NPI: 1407040884) practices hematology/oncology in the Cincinnati, OH-KY-IN market, with the plurality of this provider's patient population coming from Clermont, OH. This provider's primary affiliated billing organization is ONCOLOGY HEMATOLOGY CARE INC (NPI: 1790778041; TIN: 311106418) and primary practice location at 45245-1898. Johns is affiliated with the Mercy Health Select, LLC (ACO ID: A1215), participating under the MSSP model.

Johns' data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 660 traditional Medicare patients, billed 145,631 HCPCS/CPT codes, and received $2,485,247 in Medicare payments. The top billing code was 99214 (Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more). Part D data shows 3,264 prescription claims across 508 beneficiaries totaling $4,867,536 in drug costs, led by Calquence (Acalabrutinib Maleate). DME data shows 23 claims. Open Payments data shows 72 records totaling $139,846. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing has risen steadily, from $170,833 to $2,485,247. Similarly, Part D prescription costs have risen steadily, from $360,293 to $4,867,536. In contrast, DME billing represents a smaller volume and fell sharply in recent years, from $2,737 to $1,270.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Year	Patients	Clm Lines	Payment
2015	315	19,265	$170,833
2016	506	116,805	$1,134,627
2017	497	130,838	$1,329,854
2018	609	151,343	$2,247,748
2019	691	168,044	$2,836,521
2020	669	165,312	$2,688,000
2021	678	148,801	$2,353,218
2022	629	127,412	$1,849,583
2023	678	145,952	$2,306,124
2024	660	145,631	$2,485,247

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Year	Patients	Claims	Drug Cost
2015	161	940	$360,293
2016	196	1,276	$594,495
2017	204	1,455	$1,192,896
2018	328	2,189	$2,017,607
2019	345	2,331	$3,178,703
2020	386	2,425	$3,169,752
2021	403	2,670	$3,716,288
2022	403	2,619	$3,643,565
2023	442	2,712	$3,510,673
2024	508	3,264	$4,867,536

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

Year	Patients	Claims	Payment
2015	N/R	12	$688
2016	N/R	78	$2,869
2017	22	256	$11,563
2018	47	290	$12,141
2019	33	300	$10,541
2020	N/R	169	$7,733
2021	N/R	153	$9,073
2022	N/R	190	$8,692
2023	N/R	47	$1,708
2024	N/R	23	$1,270

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

Code	Description	Patients	Clm Lines	Total Payment
99214	Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more	171	319	$90
99213	Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more	421	778	$59
G2211	Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's	337	617	$11
80053	Blood test, comprehensive group of blood chemicals	336	876	$10
85025	Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count	398	1,112	$8

Top 5 Part D drugs in 2024

By total drug costs.

Drug	Generic	Claims	Total Day Supply	Total Drug Cost
Calquence	Acalabrutinib Maleate	107	3,210	$1,597,376
Lenalidomide	Lenalidomide	31	833	$524,030
Qinlock	Ripretinib	11	330	$457,839
Verzenio	Abemaciclib	20	560	$297,791
Tasigna	Nilotinib Hcl	12	336	$237,370

Top 5 DME services in 2024

By Total Medicare Payment Amount.

HCPCS Code	HCPCS Description	Supplier Rental Indicator	Total Supplier Beneficiaries	Total Supplier Claims	Total Medicare Payment Amount
E1390	Oxygen concentrator, single delivery port, capable of delivering 85 percent or greater oxygen concentration at the prescribed flow rate	Y	N/R	11	$827
E0657	Segmental pneumatic appliance for use with pneumatic compressor, chest	Y	N/R	12	$443

Open Payments Summary in 2024

Category	Definition	Records	Total Reported Amount	Top Related Entity
General Payments	Reported payment or transfer-of-value amount.	20	$1,329	Novartis Pharmaceuticals Corporation
Research Payments	Reported research-related payment or transfer-of-value amount.	52	$138,517	BioNTech SE
Ownership / Investment Interests	Reported value of ownership or investment interests.	0	$0	N/R

Explore More Providers

FAQ

What Medicare data is available for Mark E. Johns, MD?

Tedicare shows public-source Medicare data for Mark E. Johns, MD (NPI 1407040884), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Mark E. Johns, MD have ACO affiliation data?

Mark E. Johns, MD is shown with ACO affiliation data for Mercy Health Select, LLC (MSSP, ACO ID A1215).

What billing organization is linked to Mark E. Johns, MD?

Mark E. Johns, MD is linked to ONCOLOGY HEMATOLOGY CARE INC (billing NPI 1790778041) in the available physician profile data.

Does Mark E. Johns, MD have Open Payments data?

Mark E. Johns, MD has 72 connected Open Payments records in the available 2024 summary data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.